Daiichi Buys Rights To ArQule Cancer Drug Still In Trials
This article was originally published in PharmAsia News
Daiichi Sankyo and ArQule of the United States have joined forces to develop cancer drugs, beginning with a $75 million investment. The upfront payment by Daiichi is for rights to ArQule's ARQ 197 c-Met inhibitor for liver and other cancers, now in clinical trials in the U.S. The purchase gives Daiichi rights only in China, Taiwan and South Korea, and not in Japan. Trials so far have shown effectiveness for the drug without severe side effects. (Click here for more - a subscription may be required
You may also be interested in...
The China National Biotec Group has filed the first application in China for the broad use of a COVID-19 vaccine, days after the national regulatory agency released review guidelines for the conditional approval of such products.
More patent-related turbulence appears ahead for Novartis’s sacubitril/valsartan combination in India, with Torrent emerging as the new challenger. The companies are engaged in a legal battle and the Indian firm is also seeking a revocation of the patent on the star heart failure treatment.
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.